Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

PAS Date: December 31, 2018.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 14
Posts 1,457
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019 PR Newswire (US) - 10/15/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:21:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/2/2019 4:17:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2019 6:33:32 AM
Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors PR Newswire (US) - 9/19/2019 8:20:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/5/2019 7:06:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/5/2019 7:03:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2019 6:05:36 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences PR Newswire (US) - 8/22/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2019 4:20:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/14/2019 4:15:44 PM
Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire (US) - 8/13/2019 7:32:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/12/2019 4:46:55 PM
Portola Pharmaceuticals Announces Proposed Offering of Common Stock PR Newswire (US) - 8/12/2019 4:43:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/9/2019 6:51:55 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/7/2019 5:16:00 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 8/7/2019 5:12:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:32:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:13:13 PM
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire (US) - 8/7/2019 4:05:00 PM
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe PR Newswire (US) - 8/6/2019 8:30:00 AM
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portol... PR Newswire (US) - 8/5/2019 7:00:00 AM
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 PR Newswire (US) - 7/17/2019 8:30:00 AM
Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) ... PR Newswire (US) - 7/8/2019 8:30:00 AM
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re... PR Newswire (US) - 6/19/2019 11:05:00 AM
H2R   Tuesday, 09/11/18 06:43:47 PM
Re: None
Post # of 182 
PAS Date: December 31, 2018.

The Target is Set!!!

http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=2366974
Quote:

U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process

Action Date Set for December 31, 2018

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company’s Prior Approval Supplement (PAS) filing for the large-scale Generation 2 manufacturing process for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo]. The PAS has been assigned a Prescription Drug User Fee Act (PDUFA) date of December 31, 2018. If accepted and approved, the PAS will allow for the broad commercial launch of Andexxa in the United States.

Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations, and was approved on May 3, 2018 under the FDA's Accelerated Approval pathway. It is the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.





Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist